

Scott D Berkowitz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6906787/publications.pdf>

Version: 2024-02-01

172
papers

28,819
citations

17440

63
h-index

4991

167
g-index

183
all docs

183
docs citations

183
times ranked

17562
citing authors

#	ARTICLE	IF	CITATIONS
1	Low-dose rivaroxaban and aspirin among patients with peripheral artery disease: a meta-analysis of the COMPASS and VOYAGER trials. <i>European Journal of Preventive Cardiology</i> , 2022, 29, e181-e189.	1.8	18
2	Frequency and Patterns of Brain Infarction in Patients With Embolic Stroke of Undetermined Source: NAVIGATE ESUS Trial. <i>Stroke</i> , 2022, 53, 45-52.	2.0	8
3	Rivaroxaban versus aspirin for prevention of covert brain infarcts in patients with embolic stroke of undetermined source: NAVIGATE ESUS MRI substudy. <i>International Journal of Stroke</i> , 2022, 17, 799-805.	5.9	8
4	Prevention of arterial and venous thrombotic events in symptomatic peripheral arterial disease patients after lower extremity revascularization in the VOYAGER PAD trial: Dual anticoagulant/antiplatelet regimen vs antiplatelet therapy alone. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 1193-1205.	3.8	3
5	Improvement in walking impairment following surgical and endovascular revascularization: Insights from VOYAGER PAD. <i>Vascular Medicine</i> , 2022, 27, 343-349.	1.5	3
6	Sex-Based Differences in Outcomes Following Peripheral Artery Revascularization: Insights From VOYAGER PAD. <i>Journal of the American Heart Association</i> , 2022, 11, .	3.7	8
7	Rivaroxaban and Risk of Venous Thromboembolism in Patients With Symptomatic Peripheral Artery Disease After Lower Extremity Revascularization. <i>JAMA Network Open</i> , 2022, 5, e2215580.	5.9	11
8	Rivaroxaban and Aspirin in Patients With Symptomatic Lower Extremity Peripheral Artery Disease. <i>JAMA Cardiology</i> , 2021, 6, 21-29.	6.1	33
9	Efficacy and safety of rivaroxaban plus aspirin in women and men with chronic coronary or peripheral artery disease. <i>Cardiovascular Research</i> , 2021, 117, 942-949.	3.8	15
10	Microbleeds and the Effect of Anticoagulation in Patients With Embolic Stroke of Undetermined Source. <i>JAMA Neurology</i> , 2021, 78, 11.	9.0	28
11	Rivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial. <i>Journal of the American College of Cardiology</i> , 2021, 77, 511-525.	2.8	11
12	Regional, sex, and age differences in diagnostic testing among participants in the NAVIGATE-ESUS trial. <i>International Journal of Stroke</i> , 2021, 16, 55-62.	5.9	2
13	Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery disease. <i>Heart</i> , 2021, 107, 1130-1137.	2.9	6
14	Rivaroxaban versus warfarin in patients with atrial fibrillation enrolled in Latin America: Insights from ROCKET AF. <i>American Heart Journal</i> , 2021, 236, 4-12.	2.7	4
15	Pharmacotherapy for diabetes and stroke risk: Results from ROCKET AF. <i>Heart Rhythm O2</i> , 2021, 2, 215-222.	1.7	1
16	Total Ischemic Event Reduction With Rivaroxaban After Peripheral Arterial Revascularization in the VOYAGER PAD Trial. <i>Journal of the American College of Cardiology</i> , 2021, 78, 317-326.	2.8	30
17	Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease. <i>Journal of the American College of Cardiology</i> , 2021, 78, 14-23.	2.8	31
18	Effect of Rivaroxaban and Aspirin in Patients With Peripheral Artery Disease Undergoing Surgical Revascularization: Insights From the VOYAGER PAD Trial. <i>Circulation</i> , 2021, 144, 1104-1116.	1.6	25

#	ARTICLE	IF	CITATIONS
19	Clinical factors associated with peripheral artery disease in patients with documented coronary artery disease: A post hoc analysis of the COMPASS trial. <i>Atherosclerosis</i> , 2021, 331, 38-44.	0.8	1
20	Risk stratification of cardiovascular complications using CHA2DS2-VASc and CHADS2 scores in chronic atherosclerotic cardiovascular disease. <i>International Journal of Cardiology</i> , 2021, 337, 9-15.	1.7	4
21	Rivaroxaban in Patients With Recent Peripheral Artery Revascularization and Renal Impairment. <i>Journal of the American College of Cardiology</i> , 2021, 78, 757-759.	2.8	2
22	Low-dose rivaroxaban plus aspirin in older patients with peripheral artery disease undergoing acute limb revascularization: insights from the VOYAGER PAD trial. <i>European Heart Journal</i> , 2021, 42, 4040-4048.	2.2	13
23	Termination Based on Event Accrual in Per Protocol Versus Intention to Treat in the ROCKET AF Trial. <i>Journal of the American Heart Association</i> , 2021, 10, e022485.	3.7	0
24	Reduction in Acute Limb Ischemia With Rivaroxaban Versus Placebo in Peripheral Artery Disease After Lower Extremity Revascularization: Insights From VOYAGER PAD. <i>Circulation</i> , 2021, 144, 1831-1841.	1.6	19
25	Safety and Effectiveness of Paclitaxel Drug-Coated Devices in Peripheral Artery Revascularization. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1768-1778.	2.8	19
26	Risk factors and clinical outcomes in chronic coronary and peripheral artery disease: An analysis of the randomized, double-blind COMPASS trial. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 296-307.	1.8	28
27	Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial. <i>Lancet Haematology</i> , 2020, 7, e18-e27.	4.6	173
28	Atrial Cardiopathy and Nonstenosing Large Artery Plaque in Patients With Embolic Stroke of Undetermined Source. <i>Stroke</i> , 2020, 51, 938-943.	2.0	25
29	Safety and efficacy of anticoagulant therapy in pediatric catheter-related venous thrombosis (EINSTEIN-Jr CVC-VTE). <i>Blood Advances</i> , 2020, 4, 4632-4639.	5.2	35
30	Intracranial and systemic atherosclerosis in the NAVIGATE ESUS trial: Recurrent stroke risk and response to antithrombotic therapy. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2020, 29, 104936.	1.6	17
31	Characteristics of Recurrent Ischemic Stroke After Embolic Stroke of Undetermined Source. <i>JAMA Neurology</i> , 2020, 77, 1233.	9.0	37
32	Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline. <i>Stroke</i> , 2020, 51, 2901-2909.	2.0	15
33	Rivaroxaban and Aspirin in Peripheral Artery Disease Lower Extremity Revascularization. <i>Circulation</i> , 2020, 142, 2219-2230.	1.6	58
34	Frequency and Predictors of Major Bleeding in Patients With Embolic Strokes of Undetermined Source. <i>Stroke</i> , 2020, 51, 2139-2147.	2.0	7
35	Rivaroxaban Plus Aspirin Versus Aspirin Alone in Patients With Prior Percutaneous Coronary Intervention (COMPASS-PCI). <i>Circulation</i> , 2020, 141, 1141-1151.	1.6	39
36	Rivaroxaban in Peripheral Artery Disease after Revascularization. <i>New England Journal of Medicine</i> , 2020, 382, 1994-2004.	27.0	566

#	ARTICLE	IF	CITATIONS
37	Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease. <i>Circulation</i> , 2020, 141, 1841-1854.	1.6	96
38	High-Sensitivity Cardiac Troponin T for Risk Stratification in Patients With Embolic Stroke of Undetermined Source. <i>Stroke</i> , 2020, 51, 2386-2394.	2.0	18
39	Rivaroxaban versus aspirin for secondary prevention of ischaemic stroke in patients with cancer: a subgroup analysis of the NAVIGATE ESUS randomized trial. <i>European Journal of Neurology</i> , 2020, 27, 841-848.	3.3	25
40	Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 130.	7.4	146
41	Rivaroxaban for treatment of pediatric venous thromboembolism. An Einsteinâ€r phase 3 doseâ€exposureâ€response evaluation. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1672-1685.	3.8	52
42	Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the treatment of venous thromboembolism. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 50, 1-11.	2.1	10
43	Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in patients with non-valvular atrial fibrillation. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 50, 20-29.	2.1	14
44	Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the prevention of venous thromboembolism. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 50, 12-19.	2.1	6
45	Potential Embolic Sources and Outcomes in Embolic Stroke of Undetermined Source in the NAVIGATE-ESUS Trial. <i>Stroke</i> , 2020, 51, 1797-1804.	2.0	54
46	Abstract 14170: Reduction in Venous Thromboembolism With Rivaroxaban versus Placebo in Peripheral Artery Disease After Lower Extremity Revascularization: Insights From VOYAGER PAD. <i>Circulation</i> , 2020, 142, .	1.6	1
47	Safety and efficacy of rivaroxaban in pediatric cerebral venous thrombosis (EINSTEIN-Jr CVT). <i>Blood Advances</i> , 2020, 4, 6250-6258.	5.2	49
48	Rationale, design, and baseline participant characteristics in the MRI and cognitive substudy of the cardiovascular outcomes for people using anticoagulation strategies trial. <i>International Journal of Stroke</i> , 2019, 14, 270-281.	5.9	11
49	Efficacy and Safety of Rivaroxaban Versus Aspirin in Embolic Stroke of Undetermined Source and Carotid Atherosclerosis. <i>Stroke</i> , 2019, 50, 2477-2485.	2.0	72
50	Influence of model-predicted rivaroxaban exposure and patient characteristics on efficacy and safety outcomes in patients with acute coronary syndrome. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2019, 13, 175394471986364.	2.1	6
51	Patient-Reported Satisfaction and Study Drug Discontinuation: Post-Hoc Analysis of Findings from ROCKET AF. <i>Cardiology and Therapy</i> , 2019, 8, 283-295.	2.6	2
52	Enhancing the Quality of Rivaroxaban Exposure Estimates Using Prothrombin Time in the Absence of Pharmacokinetic Sampling. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2019, 8, 805-814.	2.5	9
53	Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial. <i>European Heart Journal</i> , 2019, 40, 3771-3778a.	2.2	34
54	Bleeding and New Cancer Diagnosis in Patients With Atherosclerosis. <i>Circulation</i> , 2019, 140, 1451-1459.	1.6	36

#	ARTICLE	IF	CITATIONS
55	Aortic Arch Atherosclerosis in Patients With Embolic Stroke of Undetermined Source. <i>Stroke</i> , 2019, 50, 3184-3190.	2.0	78
56	Major Bleeding in Patients With Coronary&or Peripheral Artery Disease Treated With Rivaroxaban Plus Aspirin. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1519-1528.	2.8	30
57	Stroke Outcomes in the COMPASS Trial. <i>Circulation</i> , 2019, 139, 1134-1145.	1.6	118
58	Branch atheromatous disease diagnosed as embolic stroke of undetermined source: A sub-analysis of NAVIGATE ESUS. <i>International Journal of Stroke</i> , 2019, 14, 915-922.	5.9	22
59	Predictors of Recurrent Ischemic Stroke in Patients with Embolic Strokes of Undetermined Source and Effects of Rivaroxaban Versus Aspirin According to Risk Status: The NAVIGATE ESUS Trial. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2019, 28, 2273-2279.	1.6	27
60	Recurrent Stroke With Rivaroxaban Compared With Aspirin According to Predictors of Atrial Fibrillation. <i>JAMA Neurology</i> , 2019, 76, 764.	9.0	147
61	Efficacy and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and a history of cancer: observations from ROCKET AF. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2019, 5, 145-152.	4.0	75
62	Net clinical benefit of rivaroxaban compared with warfarin in atrial fibrillation: Results from ROCKET AF. <i>International Journal of Cardiology</i> , 2018, 257, 78-83.	1.7	10
63	Impact of polyvascular disease on patients with atrial fibrillation: Insights from ROCKET AF. <i>American Heart Journal</i> , 2018, 200, 102-109.	2.7	6
64	Efficacy and safety of rivaroxaban compared with warfarin in patients with carotid artery disease and nonvalvular atrial fibrillation: Insights from the ROCKET AF trial. <i>Clinical Cardiology</i> , 2018, 41, 39-45.	1.8	11
65	Rationale and design for the Vascular Outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (VOYAGER PAD). <i>American Heart Journal</i> , 2018, 199, 83-91.	2.7	104
66	Characterization of Patients with Embolic Strokes of Undetermined Source in the NAVIGATE ESUS Randomized Trial. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2018, 27, 1673-1682.	1.6	46
67	Is there a role for pharmacokinetic/pharmacodynamic-guided dosing for novel oral anticoagulants?. <i>American Heart Journal</i> , 2018, 199, 59-67.	2.7	36
68	Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2018, 391, 205-218.	13.7	426
69	Clinical presentation and therapeutic management of venous thrombosis in young children: a retrospective analysis. <i>Thrombosis Journal</i> , 2018, 16, 29.	2.1	14
70	Rivaroxaban versus standard anticoagulation for acute venous thromboembolism in childhood. Design of the EINSTEIN-Jr phase III study. <i>Thrombosis Journal</i> , 2018, 16, 34.	2.1	28
71	Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial. <i>Lancet Neurology, The</i> , 2018, 17, 1053-1060.	10.2	146
72	Selective Serotonin Reuptake Inhibitors and Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation: An Analysis From the ROCKET AF Trial. <i>Journal of the American Heart Association</i> , 2018, 7, e008755.	3.7	21

#	ARTICLE	IF	CITATIONS
73	Comment on model-based meta-analysis to evaluate optimal doses of direct oral factor Xa inhibitors in atrial fibrillation patients. <i>Blood Advances</i> , 2018, 2, 3193-3195.	5.2	0
74	Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source. <i>New England Journal of Medicine</i> , 2018, 378, 2191-2201.	27.0	730
75	Treatment Consistency Across Levels of Baseline Renal Function With Rivaroxaban or Warfarin. <i>Circulation</i> , 2017, 135, 1001-1003.	1.6	30
76	Efficacy and safety of rivaroxaban versus warfarin in patients from mainland China with nonvalvular atrial fibrillation: A subgroup analysis from the ROCKET AF trial. <i>Thrombosis Research</i> , 2017, 156, 184-190.	1.7	11
77	Safety and Efficacy of Rivaroxaban in Patients With Cardiac Implantable Electronic Devices: Observations From the ROCKET AF Trial. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	8
78	Efficacy and Safety of Rivaroxaban Versus Warfarin in Patients Taking Nondihydropyridine Calcium Channel Blockers for Atrial Fibrillation (from the ROCKET AF Trial). <i>American Journal of Cardiology</i> , 2017, 120, 588-594.	1.6	36
79	Relation of Risk of Stroke in Patients With Atrial Fibrillation to Body Mass Index (from Patients) <i>Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 5</i>	1.6	74
80	Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism. <i>New England Journal of Medicine</i> , 2017, 376, 1211-1222.	27.0	577
81	Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2017, 377, 1319-1330.	27.0	1,745
82	Outcome of Patients Receiving Thrombolytic Therapy While on Rivaroxaban for Nonvalvular Atrial Fibrillation (from Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5</i> <i>Cardiology</i> , 2017, 120, 1837-1840.	1.6	10
83	Rivaroxaban for secondary stroke prevention in patients with embolic strokes of undetermined source: Design of the NAVIGATE ESUS randomized trial. <i>European Stroke Journal</i> , 2016, 1, 146-154.	5.5	83
84	Response by Piccini et al to Letters Regarding Article, "Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation" <i>Circulation</i> , 2016, 134, e7-8.	1.6	1
85	Embolic strokes of undetermined source: Prevalence and patient features in the ESUS Global Registry. <i>International Journal of Stroke</i> , 2016, 11, 526-533.	5.9	113
86	Hospitalizations in patients with atrial fibrillation: an analysis from ROCKET AF. <i>Europace</i> , 2016, 18, 1135-1142.	1.7	31
87	Use of Dual Antiplatelet Therapy and Patient Outcomes in Those Undergoing Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1694-1702.	2.9	21
88	Blood pressure control and stroke or bleeding risk in anticoagulated patients with atrial fibrillation: Results from the ROCKET AF Trial. <i>American Heart Journal</i> , 2016, 178, 74-84.	2.7	48
89	Use of concomitant aspirin in patients with atrial fibrillation: Findings from the ROCKET AF trial. <i>American Heart Journal</i> , 2016, 179, 77-86.	2.7	51
90	On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin. <i>Circulation</i> , 2016, 134, 37-47.	1.6	134

#	ARTICLE	IF	CITATIONS
91	Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban. <i>Heart</i> , 2016, 102, 1036-1043.	2.9	36
92	Evidence-Based Development and Rationale for Once-Daily Rivaroxaban Dosing Regimens Across Multiple Indications. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2016, 22, 412-422.	1.7	28
93	Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF. <i>Journal of the American Heart Association</i> , 2016, 5, e002197.	3.7	127
94	Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation. <i>Circulation</i> , 2016, 133, 352-360.	1.6	141
95	Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial. <i>European Heart Journal</i> , 2015, 36, 288-296.	2.2	266
96	Novel oral anticoagulants and reversal agents: Considerations for clinical development. <i>American Heart Journal</i> , 2015, 169, 751-757.	2.7	69
97	Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: The Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial). <i>American Heart Journal</i> , 2015, 170, 675-682.e8.	2.7	128
98	Cardiovascular Drug Development. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1567-1582.	2.8	168
99	Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). <i>Lancet, The</i> , 2015, 385, 2363-2370.	13.7	123
100	Gastrointestinal Bleeding in Patients With Atrial Fibrillation Treated With Rivaroxaban or Warfarin. <i>Journal of the American College of Cardiology</i> , 2015, 66, 2271-2281.	2.8	159
101	Benefit–risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplasty. <i>Vascular Health and Risk Management</i> , 2014, 10, 157.	2.3	28
102	Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial. <i>European Heart Journal</i> , 2014, 35, 3377-3385.	2.2	154
103	Comparison of three&factor and four&factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers. <i>Journal of Thrombosis and Haemostasis</i> , 2014, 12, 1428-1436.	3.8	181
104	Relationship Between Time in Therapeutic Range and Comparative Treatment Effect of Rivaroxaban and Warfarin: Results From the ROCKET AF Trial. <i>Journal of the American Heart Association</i> , 2014, 3, e000521.	3.7	94
105	Use and outcomes of antiarrhythmic therapy in patients with atrial fibrillation receiving oral anticoagulation: Results from the ROCKET AF trial. <i>Heart Rhythm</i> , 2014, 11, 925-932.	0.7	52
106	Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial. <i>European Heart Journal</i> , 2014, 35, 1873-1880.	2.2	145
107	Intracranial Hemorrhage Among Patients With Atrial Fibrillation Anticoagulated With Warfarin or Rivaroxaban. <i>Stroke</i> , 2014, 45, 1304-1312.	2.0	187
108	Factors Associated With Major Bleeding Events. <i>Journal of the American College of Cardiology</i> , 2014, 63, 891-900.	2.8	212

#	ARTICLE	IF	CITATIONS
109	Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. <i>Lancet Haematology</i> , 2014, 1, e37-e46.	4.6	244
110	Allogeneic Blood Transfusions and Postoperative Infections After Total Hip or Knee Arthroplasty. <i>Journal of Bone and Joint Surgery - Series A</i> , 2014, 96, 272-278.	3.0	197
111	Rivaroxaban for Stroke Prevention in East Asian Patients From the ROCKET AF Trial. <i>Stroke</i> , 2014, 45, 1739-1747.	2.0	142
112	Complication Rates After Hip or Knee Arthroplasty in Morbidly Obese Patients. <i>Clinical Orthopaedics and Related Research</i> , 2013, 471, 3358-3366.	1.5	160
113	Outcomes of Discontinuing Rivaroxaban Compared With Warfarin in Patients With Nonvalvular Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2013, 61, 651-658.	2.8	181
114	Antithrombotic outcome trials in acute coronary syndromes: seeking the optimal balance between safety and efficacy. <i>European Heart Journal</i> , 2013, 34, 1621-1629.	2.2	9
115	Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. <i>Thrombosis Journal</i> , 2013, 11, 21.	2.1	471
116	Is thrombosis a contributor to heart failure pathophysiology? Possible mechanisms, therapeutic opportunities, and clinical investigation challenges. <i>International Journal of Cardiology</i> , 2013, 167, 1772-1782.	1.7	67
117	CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH ATRIAL FIBRILLATION AND SIGNIFICANT VALVULAR LESIONS: EXPERIENCE FROM THE ROCKET AF TRIAL. <i>Journal of the American College of Cardiology</i> , 2013, 61, E282.	2.8	2
118	Rivaroxaban: a novel oral anticoagulant for the prevention and treatment of several thrombotic-mediated conditions. <i>Annals of the New York Academy of Sciences</i> , 2013, 1291, 42-55.	3.8	18
119	Incidence of neuraxial haematoma after total hip or knee surgery: RECORD programme (rivaroxaban vs. enoxaparin). <i>Acta Anaesthesiologica Scandinavica</i> , 2013, 57, 565-572.	1.6	33
120	Efficacy and Safety of Rivaroxaban in Patients With Heart Failure and Nonvalvular Atrial Fibrillation. <i>Circulation: Heart Failure</i> , 2013, 6, 740-747.	3.9	102
121	End of Study Transition From Study Drug to Open-Label Vitamin K Antagonist Therapy. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2013, 6, 470-478.	2.2	39
122	Clinical Outcomes With Rivaroxaban in Patients Transitioned From Vitamin K Antagonist Therapy. <i>Annals of Internal Medicine</i> , 2013, 158, 861.	3.9	46
123	The discovery of rivaroxaban: translating preclinical assessments into clinical practice. <i>Frontiers in Pharmacology</i> , 2013, 4, 145.	3.5	15
124	Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism. <i>New England Journal of Medicine</i> , 2012, 366, 1287-1297.	27.0	2,080
125	The effects of rivaroxaban on the complications of surgery after total hip or knee replacement. <i>Journal of Bone and Joint Surgery: British Volume</i> , 2012, 94-B, 1573-1578.	3.4	43
126	Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2011, 365, 883-891.	27.0	8,006

#	ARTICLE	IF	CITATIONS
127	Evaluation of Drug-Induced Serious Hepatotoxicity (eDISH). <i>Drug Safety</i> , 2011, 34, 243-252.	3.2	98
128	Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. <i>Thrombosis and Haemostasis</i> , 2011, 105, 444-453.	3.4	250
129	The discovery and development of rivaroxaban. <i>Annals of the New York Academy of Sciences</i> , 2011, 1222, 64-75.	3.8	27
130	Oral Rivaroxaban for Symptomatic Venous Thromboembolism. <i>New England Journal of Medicine</i> , 2010, 363, 2499-2510.	27.0	2,807
131	Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. <i>Lancet, The</i> , 2009, 373, 1673-1680.	13.7	898
132	Once-Daily Oral Rivaroxaban Compared with Subcutaneous Enoxaparin Every 12 Hours for Thromboprophylaxis after Total Knee Replacement: RECORD4. <i>Blood</i> , 2008, 112, 35-35.	1.4	9
133	Effects of Age, Weight, Gender and Renal Function in a Pooled Analysis of Four Phase III Studies of Rivaroxaban for Prevention of Venous Thromboembolism after Major Orthopedic Surgery. <i>Blood</i> , 2008, 112, 436-436.	1.4	8
134	Oral Direct Thrombin Inhibitor Ximelagatran Compared with Warfarin for the Prevention of Venous Thromboembolism After Total Knee Arthroplasty. <i>Journal of Bone and Joint Surgery - Series A</i> , 2005, 87, 2169.	3.0	47
135	Ximelagatran vs Low-Molecular-Weight Heparin and Warfarin for the Treatment of Deep Vein Thrombosis. <i>JAMA - Journal of the American Medical Association</i> , 2005, 293, 681.	7.4	274
136	ORAL DIRECT THROMBIN INHIBITOR XIMELAGATRAN COMPARED WITH WARFARIN FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM AFTER TOTAL KNEE ARTHROPLASTY. <i>Journal of Bone and Joint Surgery - Series A</i> , 2005, 87, 2169-2177.	3.0	24
137	Bleeding Indicators and Wound Complications with Ximelagatran and Warfarin after TKR: Findings from 3 Clinical Trials.. <i>Blood</i> , 2004, 104, 1771-1771.	1.4	0
138	Oral heparin administration with a novel drug delivery agent (SNAC) in healthy volunteers and patients undergoing elective total hip arthroplasty. <i>Journal of Thrombosis and Haemostasis</i> , 2003, 1, 1914-1919.	3.8	46
139	Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind study. <i>Journal of Thrombosis and Haemostasis</i> , 2003, 1, 2119-2130.	3.8	141
140	Comparison of Ximelagatran with Warfarin for the Prevention of Venous Thromboembolism after Total Knee Replacement. <i>New England Journal of Medicine</i> , 2003, 349, 1703-1712.	27.0	317
141	Ximelagatran versus Warfarin for the Prevention of Venous Thromboembolism after Total Knee Arthroplasty. <i>Annals of Internal Medicine</i> , 2002, 137, 648.	3.9	187
142	Heparin dosing and outcome in acute coronary syndromes: The GUSTO-IIb experience. <i>American Heart Journal</i> , 2002, 144, 73-80.	2.7	28
143	Determination of platelet aggregation inhibition during percutaneous coronary intervention with the platelet function analyzer PFA-100. <i>American Heart Journal</i> , 2002, 144, 151-158.	2.7	36
144	The determinants of activated partial thromboplastin time, relation of activated partial thromboplastin time to clinical outcomes, and optimal dosing regimens for heparin treated patients with acute coronary syndromes: a review of GUSTO-IIb. <i>Journal of Thrombosis and Thrombolysis</i> , 2002, 14, 91-101.	2.1	31

#	ARTICLE	IF	CITATIONS
145	New heparin dosing recommendations for patients with acute coronary syndromes. <i>American Journal of Medicine</i> , 2001, 110, 641-650.	1.5	30
146	Rapid assessment of glycoprotein IIb/IIIa blockade with the platelet function analyzer (PFA-100) during percutaneous coronary intervention. <i>American Heart Journal</i> , 2001, 141, 226-233.	2.7	68
147	Antithrombotic therapy after prosthetic cardiac valve implantation: Potential novel antithrombotic therapies. <i>American Heart Journal</i> , 2001, 142, 7-13.	2.7	13
148	Comparison of two aspirin doses on ischemic stroke in post-myocardial infarction patients in the warfarin (Coumadin) Aspirin Reinfarction Study (CARS). <i>American Journal of Cardiology</i> , 2001, 88, 541-546.	1.6	23
149	Prospective comparison of hemorrhagic complications after treatment with enoxaparin versus unfractionated heparin for unstable angina pectoris or non-ST-segment elevation acute myocardial infarction. <i>American Journal of Cardiology</i> , 2001, 88, 1230-1234.	1.6	33
150	Argatroban Anticoagulant Therapy in Patients With Heparin-Induced Thrombocytopenia. <i>Circulation</i> , 2001, 103, 1838-1843.	1.6	661
151	Comparison of the Oral Direct Thrombin Inhibitor Ximelagatran With Enoxaparin as Prophylaxis Against Venous Thromboembolism After Total Knee Replacement. <i>Archives of Internal Medicine</i> , 2001, 161, 2215.	3.8	150
152	Current Knowledge of the Platelet Glycoprotein IIb/IIIa Receptor Antagonists for the Treatment of Coronary Artery Disease. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 2000, 30, 27-43.	0.3	6
153	Efficacy of abciximab readministration in coronary intervention. <i>American Journal of Cardiology</i> , 2000, 85, 435-440.	1.6	48
154	Clinical correlates and course of thrombocytopenia during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade. <i>American Heart Journal</i> , 2000, 140, 74-80.	2.7	83
155	Clinical Significance of Thrombocytopenia During a Non-ST-Elevation Acute Coronary Syndrome. <i>Circulation</i> , 1999, 99, 2892-2900.	1.6	146
156	Understanding thrombocytopenia and antigenicity with glycoprotein IIb-IIIa inhibitors. <i>American Heart Journal</i> , 1999, 138, S317-S326.	2.7	59
157	Bleeding complications with platelet glycoprotein IIb/IIIa receptor antagonists. <i>Current Opinion in Hematology</i> , 1999, 6, 334-341.	2.5	26
158	Modifiable Risk Factors for Vascular Access Site Complications in the IMPACT II Trial of Angioplasty With Versus Without Eptifibatide. <i>Journal of the American College of Cardiology</i> , 1998, 31, 1518-1524.	2.8	80
159	Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. <i>Journal of the American College of Cardiology</i> , 1998, 32, 311-319.	2.8	141
160	Progress in point-of-care laboratory testing for assessing platelet function. <i>American Heart Journal</i> , 1998, 136, s51-s65.	2.7	14
161	Relation between inhibition of platelet aggregation and clinical outcomes. <i>American Heart Journal</i> , 1998, 136, s43-s50.	2.7	24
162	Economic Assessment of Low-Molecular-Weight Heparin (Enoxaparin) Versus Unfractionated Heparin in Acute Coronary Syndrome Patients. <i>Circulation</i> , 1998, 97, 1702-1707.	1.6	163

#	ARTICLE	IF	CITATIONS
163	Glycoprotein IIb/IIIa Integrin Blockade. <i>Circulation</i> , 1998, 98, 2629-2635.	1.6	117
164	Hemodilution With Other Blood Reinfusion Techniques in Total Hip Arthroplasty. <i>Clinical Orthopaedics and Related Research</i> , 1997, 339, 132-139.	1.5	38
165	Coagulation complicating cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia receiving the heparinoid, danaparoid sodium. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 1997, 11, 875-877.	1.3	17
166	Efficacy and Safety of Low Molecular Weight Heparin (Ardeparin Sodium) Compared to Warfarin for the Prevention of Venous Thromboembolism after Total Knee Replacement Surgery: A Double-blind, Dose-ranging Study. <i>Thrombosis and Haemostasis</i> , 1997, 77, 032-038.	3.4	96
167	Incidence and Predictors of Bleeding After Contemporary Thrombolytic Therapy for Myocardial Infarction. <i>Circulation</i> , 1997, 95, 2508-2516.	1.6	194
168	Acute Profound Thrombocytopenia After c7E3 Fab (Abciximab) Therapy. <i>Circulation</i> , 1997, 95, 809-813.	1.6	193
169	Vascular access site complications during angioplasty with glycoprotein IIb/IIIa receptor inhibition in the IMPACT II trial. <i>Journal of the American College of Cardiology</i> , 1996, 27, 360.	2.8	2
170	Analysis of the occurrence and clinical significance of thrombocytopenis with c7E3 (abciximab) in the EPIC trial. <i>Journal of the American College of Cardiology</i> , 1996, 27, 82.	2.8	3
171	Thrombin and fibrin activity in patients treated with enoxaparin, ticlopidine and aspirin versus the conventional coumadin regimen after elective stenting: The ENTICES trial. <i>Journal of the American College of Cardiology</i> , 1996, 27, 334.	2.8	4
172	TREATMENT OF ESTABLISHED DEEP VEIN THROMBOSIS: A REVIEW OF THE THERAPEUTIC ARMAMENTARIUM. <i>Orthopedics</i> , 1995, 18, 18-20.	1.1	5